|Articles|March 1, 2009

Pharmaceutical Executive

  • Pharmaceutical Executive-03-01-2009
  • Volume 0
  • Issue 0

Saatchi & Saatchi for Sanofi-Aventis's Ambien CR

Author(s)Brittany Agro

Ambien CR, the sleep medication that "helps you fall asleep fast and stay asleep" caught the eyes (and ears!) of consumers with, well, a rooster.

SILENCE YOUR ROOSTER

Saatchi & Saatchi Consumer Health + Wellness

BRAND Ambien CR CLIENT Sanofi-Aventis FROM LEFT: Andrew Curtis, copywriter; Jay Marrotte, art director

Ambien CR, the sleep medication that "helps you fall asleep fast and stay asleep" caught the eyes (and ears!) of consumers with, well, a rooster.

"The need for something that was symbolic came from the client," says Sergio Flores, associate creative director of Saatchi & Saatchi Healthcare. "We thought it would be interesting to take something that represents morning—a rooster—and have it come in the middle of the night."

DTC Ranking: Here's the year's most memorable advertising (Score based on recall 24 hours after viewing; 120=very strong)

A rooster (specially trained to stay up at night) assaults viewers with a series of antics—playing basketball, beating on drums, vacuuming—that gets consumers' attention by making them laugh. The 15-second spots, which mirror the myriad annoyances that keep people from falling or staying asleep, strike a personal chord: Whether it's worrying about a job, paying bills, etc., everyone has their own "rooster."

The spot teases consumers to visit Ambien CR's microsite, SilenceYourRooster.com. "We wanted to do it absurd, and blind enough so there'd be a better chance of getting people to go online," says Andrew Curtis, copywriter. "We wanted to create enough buzz and word of mouth to drive people to the branded microsite." In its first two weeks, the site received more than a million hits.

Articles in this issue


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.